MM016

MM016 is an investigational therapeutic candidate being developed by Mucommune. It utilizes an *in vivo* cell engineering modality, which involves the genetic or functional modification of cells directly within the patient's body. This approach aims to achieve therapeutic outcomes without the need for the complex *ex vivo* processing associated with traditional cell therapies. As of early 2024, MM016 is in the discovery phase of development. While the specific biological targets and primary disease indications remain undisclosed by the company, the program represents a novel approach to cellular reprogramming for therapeutic benefit.